https://pharminent.com/82239-2/ 2026-06-22T21:02:36Z Pharminent en 2026-06-22T21:02:33Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-june-22-2026/ 2026-06-22T20:36:19Z Pharminent en Rare Disease & Gene Therapy Digest • June 22, 2026 2026-06-22T20:36:17Z Blog https://pharminent.com/abbvie-to-acquire-apogee-therapeutics-for-nearly-11-billion-in-immunology-bet/ 2026-06-22T16:35:21Z Pharminent en AbbVie to Acquire Apogee Therapeutics for Nearly $11 Billion in Immunology Bet 2026-06-22T16:18:25Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-june-22-2026/ 2026-06-22T15:54:15Z Pharminent en Strategic News Watch • June 22, 2026 2026-06-22T15:54:13Z Blog https://pharminent.com/abbvie-climbs-post-allergan-ma-peak-with-apogee-buy/ 2026-06-22T14:50:30Z Pharminent en AbbVie climbs post-Allergan M&A peak with Apogee buy 2026-06-22T12:45:26Z Blog https://pharminent.com/lilly-bets-up-to-800m-for-bioarctics-brain-delivery-tech/ 2026-06-22T14:52:34Z Pharminent en Lilly bets up to $800M for BioArctic's brain delivery tech 2026-06-22T12:04:14Z Blog https://pharminent.com/boehringer-advances-duo-for-aggressive-cancers-into-phase-3/ 2026-06-22T14:50:32Z Pharminent en Boehringer advances duo for aggressive cancers into phase 3 2026-06-22T11:49:36Z Blog https://pharminent.com/insilico-and-sk-bio-forge-2-5bn-ai-neuroimmunity-alliance/ 2026-06-22T14:50:34Z Pharminent en Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance 2026-06-22T10:40:56Z Blog https://pharminent.com/post-marketing-oncology-studies-enabling-faster-recruitment-and-lower-costs/ 2026-06-22T14:50:35Z Pharminent en Post-marketing oncology studies: Enabling faster recruitment and lower costs 2026-06-22T10:17:06Z Blog https://pharminent.com/sun-pharma-to-acquire-innovcare-lifesciences-for-28-7m-2/ 2026-06-22T14:50:36Z Pharminent en Sun Pharma to acquire Innovcare Lifesciences for $28.7m 2026-06-22T09:03:35Z Blog https://pharminent.com/the-first-14-days-how-specialty-programs-set-patients-up-for-success/ 2026-06-22T14:53:07Z Pharminent en The first 14 days: How specialty programs set patients up for success 2026-06-22T09:00:00Z Blog https://pharminent.com/japan-approves-sanofis-sarclisa-combo-for-mm-treatment/ 2026-06-22T14:52:02Z Pharminent en Japan approves Sanofi's Sarclisa combo for MM treatment 2026-06-22T08:49:55Z Blog https://pharminent.com/week-in-review/week-in-review-intelligence-brief-june-20-2026/ 2026-06-20T21:03:20Z Pharminent en Week in Review • INTELLIGENCE BRIEF • June 20, 2026 2026-06-20T21:03:18Z Blog https://pharminent.com/market-access/market-access-intelligence-weekly-digest-june-19-2026/ 2026-06-20T20:45:25Z Pharminent en MARKET ACCESS INTELLIGENCE • Weekly Digest • June 19, 2026 2026-06-20T20:45:23Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-june-19-2026/ 2026-06-20T20:42:35Z Pharminent en Oncology Intelligence Digest • June 19, 2026 2026-06-20T20:42:33Z Blog